

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(於開曼群島註冊成立之有限公司)

(股份代號：8158)

**截至二零一七年七月三十一日止三個月
之第一季季度業績**

中國再生醫學國際有限公司(「本公司」)董事會(「董事會」)謹此公佈本公司及其附屬公司(統稱「本集團」)截至二零一七年七月三十一日止三個月之未經審核綜合業績。本公告列載本公司二零一七／二零一八年第一季季度報告(「第一季季度報告」)之全文，並符合香港聯合交易所有限公司創業板(「創業板」)證券上市規則中有關季度業績初步公告附載的資料的相關規定。第一季季度報告的印刷版本將於適當時候寄發予本公司的股東，其時並發佈於創業板的網站 www.hkgem.com 及本公司的網站 www.crmi.hk。



CRMI
中國再生醫學

CHINA REGENERATIVE MEDICINE

INTERNATIONAL LIMITED

中國再生醫學國際有限公司

Incorporated in the Cayman Islands with limited liability
於開曼群島註冊成立之有限公司

Stock Code 股份代號 : 8158

2017 / 2018
FIRST QUARTERLY REPORT
第一季季度報告



CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the “Directors”) of China Regenerative Medicine International Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

香港聯合交易所有限公司（「聯交所」）創業板（「創業板」）之特點


創業板之定位乃為相比其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市場。有意投資之人士應了解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決定。創業板之較高風險及其他特點表示創業板較適合專業及其他資深投資者。

鑒於在創業板上市之公司屬新興性質，在創業板買賣之證券可能會較在主板買賣之證券承受較大之市場波動風險，同時無法保證在創業板買賣之證券會有高流通量之市場。

香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本報告全部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。

本報告旨在遵照聯交所創業板證券上市規則（「創業板上市規則」）之規定，提供有關中國再生醫學國際有限公司（「本公司」）之資料。本公司董事（「董事」）對此共同及個別承擔全部責任。董事在作出一切合理查詢後確認，就彼等所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何其他事項，足以令致本報告或其所載任何陳述產生誤導。

FINANCIAL HIGHLIGHTS



The Company together with its subsidiaries (collectively the “Group”) recorded a revenue of approximately HK\$71.1 million for the three months ended 31 July 2017, representing an increase of 2,533% from the corresponding period of last year (2016: HK\$2.7 million) which is mainly attributable to the successful introduction of trading of medical equipment business and increase in sales of tissue engineering products during the period. Gross profit increased by 3,546% to approximately HK\$47.4 million from the corresponding period of last year which is mainly attributable to the increase in the Group’s turnover of tissue engineering products, cosmetic and others products and medical equipment.

The Group recorded a revenue of approximately HK\$47.5 million from sales of tissue engineering products for the three months ended 31 July 2017, representing an increase of 2,539% from the corresponding period of last year (2016: HK\$1.8 million) as a result of development and expansion of distribution channels to enhance the business growth.

The Group recorded a revenue of approximately HK\$0.8 million from provision of cell therapy service and sales of cell related medical equipment for the three months ended 31 July 2017, representing an increase of 167% from the corresponding period of last year (2016: HK\$0.3 million).

The Group recorded a revenue of approximately HK\$10.9 million from sales of cosmetic and others products for the three months ended 31 July 2017, representing an increase of 2,080% from the corresponding period of last year (2016: HK\$0.5 million) due to expansion of distribution channels to enhance the growth of the business.

財務摘要

本公司連同其附屬公司（統稱「本集團」）錄得截至二零一七年七月三十一日止三個月之收益為約71,100,000港元，較去年同期增加2,533%（二零一六年：2,700,000港元），該增加主要由於期內成功引入買賣醫療設備業務及組織工程產品銷售增加。毛利自去年同期增加3,546%至約47,400,000港元，此乃主要由於本集團組織工程產品、美容及其他產品及醫療設備之營業額增加所致。

截至二零一七年七月三十一日止三個月，本集團組織工程產品銷售錄得約47,500,000港元收益，較去年同期增加2,539%（二零一六年：1,800,000港元），該增加由於開發及拓展分銷渠道以推動業務增長。

截至二零一七年七月三十一日止三個月，本集團提供細胞療法服務及銷售細胞相關醫療設備錄得約800,000港元收益，較去年同期增加167%（二零一六年：300,000港元）。

截至二零一七年七月三十一日止三個月，本集團美容及其他產品銷售錄得約10,900,000港元收益，較去年同期增加2,080%（二零一六年：500,000港元），該增加由於拓展分銷渠道以推動業務增長。



Sales of medical equipment for the three months ended 31 July 2017 was approximately HK\$11.9 million, representing an increase of 119 times from the corresponding period of last year (2016: HK\$0.1 million) as the Group has made significant effort to establish distribution channels to enhance sales.

The Group's total operating expenses for the three months ended 31 July 2017 was approximately HK\$112.9 million, representing an increase of 31% as compared to the corresponding period of last year (2016: HK\$86.4 million) which is mainly attributable to increase in selling and distribution expenses as a result of increase in revenues.

The Group recorded a loss for the period for the three months ended 31 July 2017 of approximately HK\$68.0 million (2016: HK\$80.5 million). The loss was attributable to employee benefit expenses of approximately HK\$40.9 million (2016: HK\$33.4 million), advertising, marketing and promotion expenses of HK\$28.6 million (2016: HK\$2.5 million), amortisation and depreciation expenses of HK\$14.2 million (2016: HK\$13.0 million), research and development costs of HK\$8.1 million (2016: HK\$7.9 million) and exchange gain of HK\$0.7 million (2016: exchange loss of HK\$12.8 million). Loss per share attributable to the owners of the Company for the three months ended 31 July 2017 was HK0.35 cent (2016: HK0.43 cent).

The unaudited consolidated results for the three months ended 31 July 2017 and the comparison with last year are set out in the accompanying table.

截至二零一七年七月三十一日止三個月，醫療設備銷售額為約11,900,000港元，較去年同期增長119倍（二零一六年：100,000港元），此乃由於本集團致力設立分銷渠道以增加銷量。

本集團截至二零一七年七月三十一日止三個月之營運開支總額為約112,900,000港元，較去年同期增加31%（二零一六年：86,400,000港元），乃主要由於收益增加導致銷售及分銷開支增加。

截至二零一七年七月三十一日止三個月，本集團錄得期內虧損為約68,000,000港元（二零一六年：80,500,000港元）。有關虧損主要歸因於僱員福利開支約40,900,000港元（二零一六年：33,400,000港元）、廣告及市場推廣開支28,600,000港元（二零一六年：2,500,000港元）、攤銷及折舊開支14,200,000港元（二零一六年：13,000,000港元）、研發成本8,100,000港元（二零一六年：7,900,000港元）以及滙兌收益700,000港元（二零一六年：滙兌虧損12,800,000港元）。截至二零一七年七月三十一日止三個月，本公司擁有人應佔每股虧損為0.35港仙（二零一六年：0.43港仙）。

截至二零一七年七月三十一日止三個月之未經審核綜合業績及與上一年度之比較載於附表。

The board of directors (the “Board”) of the Company hereby announces the unaudited consolidated results of the Company and its subsidiaries (collectively, the “Group”) for the three months ended 31 July 2017, together with the comparative unaudited figures for the corresponding period in 2016 as follows:

本公司董事會（「董事會」）謹此公佈本公司及其附屬公司（統稱「本集團」）截至二零一七年七月三十一日止三個月之未經審核綜合業績，連同二零一六年同期之未經審核比較數字如下：

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其他全面收入表

For the three months ended 31 July 2017
截至二零一七年七月三十一日止三個月

		Three months ended 31 July 截至七月三十一日止三個月	
		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核 (restated) (經重列)
	Notes 附註		
Revenue	收益	71,065	2,720
Cost of sales	銷售成本	(23,678)	(1,443)
Gross profit	毛利	47,387	1,277
Other income	其他收入	4,956	4,536
Selling and distribution expenses	銷售及分銷開支	(36,900)	(10,057)
Administrative and other expenses	行政及其他開支	(76,046)	(76,349)
Finance costs	財務費用	(9,180)	(1,601)
Loss before income tax	除所得稅前虧損	(69,783)	(82,194)
Income tax credit	所得稅抵免	1,832	1,651
Loss for the period	期內虧損	(67,951)	(80,543)
Other comprehensive income	其他全面收入		
<i>Items that may be reclassified subsequently to profit or loss:</i>	<i>其後可能重新分類至損益之項目：</i>		
Exchange gain/(loss) on translation of financial statements of foreign operations	換算海外業務財務報表之滙兌收益／(虧損)	17,568	(14,508)
Total comprehensive income for the period	期內全面總收入	(50,383)	(95,051)



CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Cont'd)

綜合損益及其他全面收入表（續）

For the three months ended 31 July 2017
截至二零一七年七月三十一日止三個月

		Three months ended 31 July 截至七月三十一日止三個月	
		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
		Notes 附註	
Loss for the period attributable to:	以下人士應佔期內虧損：		
Owners of the Company	本公司擁有人	(61,255)	(76,355)
Non-controlling interests	非控股股東權益	(6,696)	(4,188)
		(67,951)	(80,543)
Total comprehensive income for the period attributable to:	以下人士應佔期內全面總收入：		
Owners of the Company	本公司擁有人	(44,858)	(89,838)
Non-controlling interests	非控股股東權益	(5,525)	(5,213)
		(50,383)	(95,051)
Loss per share for loss for the period attributable to owners of the Company	本公司擁有人應佔期內虧損之每股虧損	9	
– basic (HK cents)	– 基本(港仙)	(0.348)	(0.434)
– diluted (HK cents)	– 攤薄(港仙)	N/A 不適用	N/A 不適用

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動表

For the three months ended 31 July 2017
截至二零一七年七月三十一日止三個月

		Attributable to owners of the Company 本公司擁有人應佔								Non- controlling interests 非控股 股東權益	Total 合計	
		Share capital 股本 HK\$'000 千港元	Share premium 股份溢價 HK\$'000 千港元	Capital redemption reserve 資本贖回儲備 HK\$'000 千港元	Translation reserve 換算儲備 HK\$'000 千港元	Special reserve 特殊儲備 HK\$'000 千港元	Other reserve 其他儲備 HK\$'000 千港元	Share option reserve 購股權儲備 HK\$'000 千港元	Accumulated losses 累計虧損 HK\$'000 千港元	Sub-total 小計 HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元
At 1 May 2016 (audited)	於二零一六年五月一日 (經審核)	175,922	3,198,791	-	(17,747)	(200)	(410,463)	44,943	(924,882)	2,086,364	51,836	2,118,200
Loss for the period	期內虧損	-	-	-	-	-	-	-	(76,355)	(76,355)	(4,188)	(80,543)
Other comprehensive income	其他全面收入											
Exchange loss on translation of financial statements of foreign operations	換算海外業務財務報表 之匯兌虧損	-	-	-	(13,483)	-	-	-	-	(13,483)	(1,025)	(14,508)
Total comprehensive income for the period	期內全面總收入	-	-	-	(13,483)	-	-	-	(76,355)	(89,838)	(5,213)	(95,051)
Issue of share options	發行購股權	-	-	-	-	-	7,170	-	-	7,170	-	7,170
Lapse of share options	已失效購股權	-	-	-	-	-	(4,851)	4,851	-	-	-	-
Shares repurchased	已購回股份	-	-	(990)	-	-	-	-	-	(990)	-	(990)
At 31 July 2016 (Unaudited)	於二零一六年七月三十一日 (未經審核)	175,922	3,198,791	(990)	(31,230)	(200)	(410,463)	47,262	(996,386)	1,982,706	46,623	2,029,329
At 1 May 2017 (audited)	於二零一七年五月一日 (經審核)	175,858	3,196,996	-	(49,233)	(200)	(410,463)	34,674	(1,070,595)	1,877,037	30,855	1,907,892
Loss for the period	期內虧損	-	-	-	-	-	-	-	(61,255)	(61,255)	(6,696)	(67,951)
Other comprehensive income	其他全面收入											
Exchange gain on translation of financial statements of foreign operations	換算海外業務財務報表 之匯兌收益	-	-	-	16,397	-	-	-	-	16,397	1,171	17,568
Total comprehensive income for the period	期內全面總收入	-	-	-	16,397	-	-	-	(61,255)	(44,858)	(5,525)	(50,363)
Issue of share options	發行購股權	-	-	-	-	-	7,166	-	-	7,166	-	7,166
Lapse of share options	已失效購股權	-	-	-	-	-	(1,096)	1,096	-	-	-	-
Acquisition of a subsidiary	收購一間附屬公司	-	-	-	-	-	-	-	-	-	14,902	14,902
At 31 July 2017 (Unaudited)	於二零一七年七月三十一日 (未經審核)	175,858	3,196,996	-	(32,836)	(200)	(410,463)	40,744	(1,130,754)	1,839,345	40,232	1,879,577



CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Cont'd)

綜合權益變動表（續）

For the three months ended 31 July 2017
截至二零一七年七月三十一日止三個月

The special reserve represents the difference between the nominal value of the shares of the acquired subsidiaries and the nominal value of the Company's shares issued for their acquisition at the time of the Group's reorganisation in 2001.

The other reserve represents the difference between the fair value of consideration paid to increase the shareholding in a subsidiary, Shaanxi Aierfu Activtissue Engineering Company Limited and the amount of adjustment to non-controlling interests during the years ended 30 April 2011, 2013 and 2014.

特殊儲備指本集團於二零零一年重組時，被收購附屬公司股份面值與本公司就收購該等附屬公司而予以發行之股份面值之差額。

其他儲備指於截至二零一一年、二零一三年及二零一四年四月三十日止年度就增加於一間附屬公司（陝西艾爾膚組織工程有限公司）之股權所付代價之公平值與非控股股東權益調整金額之差額。

1. GENERAL INFORMATION

China Regenerative Medicine International Limited (the "Company") was incorporated as an exempted company with limited liability in the Cayman Islands under the Companies Law (Revision 2001) of Cayman Islands on 20 April 2001. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and its principal place of business is 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong. The Company's shares are listed on the Growth Enterprise Market (the "GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Company is an investment holding company. The principal activities of its subsidiaries are engaged in research and development of bio-medical and healthcare products, and medical techniques; the provision of the production and sales of tissue engineering products, stem cell products and its related by-products; as well as sales and distribution of medical products and equipment.

2. BASIS OF PREPARATION

The unaudited consolidated results for the three months ended 31 July 2017 have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKAS") and Interpretations issued by the Hong Kong Institute of Certified Public Accountants. The financial statements also include the applicable disclosure requirements of the Hong Kong Companies Ordinance and the Rules Governing the Listing of Securities on GEM of the Stock Exchange.

The unaudited consolidated results do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the annual financial statements of the Group for the year ended 30 April 2017. The accounting policies and basis of preparation adopted in the preparation of the unaudited consolidated results are consistent with those adopted in the preparation of the Group's annual financial statements for the year ended 30 April 2017 except for the impact of the adoption of a number of revised HKFRSs, which are effective for the financial year beginning on 1 May 2017. The adoption of these new HKFRSs had no material effect on the results of the Group for the current or prior accounting periods. Accordingly, no prior period adjustment has been recognised.

1. 一般資料

中國再生醫學國際有限公司（「本公司」）於二零零一年四月二十日根據開曼群島公司法（二零零一年修訂版）在開曼群島註冊成立為獲豁免有限公司。其註冊辦事處及主要營業地點之地址分別為P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands及香港灣仔告士打道108號光大中心10樓。本公司股份於香港聯合交易所有限公司（「聯交所」）創業板（「創業板」）上市。

本公司為一間投資控股公司，其附屬公司的主要業務為從事生物醫學產品和醫療保健產品及醫療技術之研發；提供組織工程產品、幹細胞產品及其相關副產品的生產及銷售；以及醫療產品及設備的銷售及分銷。

2. 編製基準

截至二零一七年七月三十一日止三個月的未經審核綜合業績乃遵照香港會計師公會頒佈之香港財務報告準則（「香港財務報告準則」），為所有適用個別香港財務報告準則、香港會計準則（「香港會計準則」）及詮釋之統稱）所編製。財務報表亦包括香港公司條例及聯交所創業板證券上市規則之適用披露規定。

本未經審核綜合業績並不包括年度財務報表所要求的所有資料及披露及應與本集團截至二零一七年四月三十日止年度之年度財務報表一併閱讀。除採納多項經修訂香港財務報告準則（於二零一七年五月一日開始之財政年度生效）之影響外，編製本未經審核綜合業績所採納之會計政策及編製基準與編製本集團截至二零一七年四月三十日止年度之年度財務報表所採納者相一致。採納該等新訂香港財務報告準則對本集團當前或過往會計期間之業績並無重大影響，故並無確認過往期間調整。



2. BASIS OF PREPARATION (Cont'd)

The Group has not early applied new and revised HKFRSs that have been issued but are not yet effective. The Directors anticipate that the application of the new and revised HKFRSs will have no material impact on the results and financial position of the Group.

The unaudited consolidated results have been reviewed by the Audit Committee of the Company.

3. SEGMENT INFORMATION

The Group identified operating segments and prepared segment information based on the regular internal financial information reported to the executive Directors for their decisions about resources allocation to the Group's business components and for their review of the performance of those components. The business components in the internal financial information reported to the executive Directors are determined following the Group's major product and service lines.

The Group has identified the following reportable segments:

Tissue engineering — production and sale of tissue engineering products;

Cell — cell therapy, and medical equipment and other services;

Cosmetic and others — production and sales of cosmetic, healthcare and others products; and

Medical equipment — trading of medical equipment.

The measurement policies the Group uses for reporting segment results under HKFRS 8 are the same as those used in its financial statements prepared under HKFRSs, except that:

- fair value gain on contingent consideration receivables
- finance costs
- income tax
- corporate income and expenses which are not directly attributable to the business activities of any operating segment

are not included in arriving at the operating results of the operating segment.

2. 編製基準 (續)

本集團並無提前應用已頒佈但尚未生效之新訂及經修訂香港財務報告準則。董事預期，應用新訂及經修訂香港財務報告準則將不會對本集團之業績及財務狀況構成重大影響。

本未經審核綜合業績已由本公司審核委員會審閱。

3. 分部資料

根據向執行董事呈報以供彼等決定本集團各業務成分的資源分配及評核該等成分表現的定期內部財務資料，本集團確認經營分部及編製分部資料。向執行董事呈報的內部財務資料內的業務成分乃依據本集團主要產品及服務種類確定。

本集團已確認以下須予呈報分部：

組織工程 — 組織工程產品生產及銷售；

細胞 — 細胞療法，以及醫療設備及其他服務；

化妝品及其他 — 化妝品、醫療保健及其他產品的生產及銷售；及

醫療設備 — 買賣醫療設備。

本集團根據香港財務報告準則第8號就報告分部業績所採用的計量政策，與根據香港財務報告準則於財務報表所採用的相同，惟以下所述者除外：

- 應收或然代價之公平值收益
- 財務費用
- 所得稅
- 並非直接歸屬於任何經營分部之業務活動的企業收入及開支

於計算經營分部的經營業績時並不包括在內。

4. REVENUE AND OTHER INCOME

The Group's turnover represents revenue from its principal activities, measured at the net invoiced value of goods sold, after allowances for returns and trade discounts during the periods are as follows:

4. 收益及其他收入

本集團之營業額指於期內來自其主要活動，按扣除退貨及貿易折扣後之已售貨品發票淨值計算之收益呈列如下：

Three months ended 31 July

截至七月三十一日止三個月

		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Sale of tissue engineering products	組織工程產品銷售	47,546	1,777
Sale of stem cell products	幹細胞產品銷售	779	313
Sale of cosmetics and others products	美容及其他產品銷售	10,866	536
Sale of medical equipments	銷售醫療設備	11,874	94
		71,065	2,720

Other income recognised during the periods is as follows:

期內已確認其他收入如下：

Three months ended 31 July

截至七月三十一日止三個月

		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Bank interest income	銀行利息收入	3,696	3,373
Fair value gain on financial assets at fair value through profit or loss	按公平值於損益列賬之金融資產之公平值收益	826	—
Interest income on loan receivables	應收貸款之利息收入	298	985
Others	其他	136	178
		4,956	4,536



5. FINANCE COSTS

		Three months ended 31 July 截至七月三十一日止三個月	
		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Interest on bank borrowings and other payables	銀行借款及其他應付款項之利息	9,180	1,601

5. 財務費用

6. LOSS BEFORE INCOME TAX

		Three months ended 31 July 截至七月三十一日止三個月	
		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Loss before income tax has been arrived at after charging/(crediting):	除所得稅前虧損已扣除/(計入)下列各項:		
Amortisation of land use rights	土地使用權攤銷	25	28
Amortisation of other intangible assets, included in administrative expenses	其他無形資產攤銷(已包括在行政開支中)	10,223	9,550
Depreciation	折舊	3,991	3,436
Equity-settled share based payments	以權益結算之股權支付費用	7,166	7,170
Exchange difference, net	滙兌差額(淨額)	(757)	12,806
Operating lease rentals in respect of office premises	辦公室物業之經營租賃租金	6,913	5,523
Research and development costs (note (i))	研發成本(附註(i))	9,702	9,045
Less: Capitalisation to other intangible assets	減:資本化至其他無形資產	(1,647)	(1,116)
		8,055	7,929
Employee benefit expenses (including directors' emoluments):	僱員福利開支(包括董事酬金):		
Salaries, wages and other benefits	薪金、工資及其他福利	31,899	25,238
Equity-settled share-based payments	以權益結算之股權支付費用	6,160	6,049
Retirement benefit scheme contributions	退休福利計劃供款	2,862	2,114

6. 除所得稅前虧損

(i) Research and development costs include depreciation and staff costs for employees in the Research and Development Department, which are also included in the amount disclosed separately above.

(i) 研發成本包括研發部門之折舊及員工成本，該等金額亦包括在上述各有關項目個別披露之金額內。

7. INCOME TAX CREDIT

No provision for profits tax has been made in the unaudited consolidated result as the Group had no assessable profits for the three months ended 31 July 2017 and 2016.

The PRC enterprise income tax of 25% (2016: 25%) is applicable to the Group's PRC subsidiaries except that Shenzhen AiNear Cornea Engineering Company Limited and Tianjin Weikai Bioeng Ltd are entitled to enjoy the tax benefit as High and New Tech Enterprises for three years starting from the year ended 31 December 2016. They are subject to preferential income tax rate of 15%.

7. 所得稅抵免

由於本集團於截至二零一七年及二零一六年七月三十一日止三個月並無產生應課稅溢利，故未經審核綜合業績並無就所得稅作出撥備。

本集團中國附屬公司適用25%（二零一六年：25%）之中國企業所得稅，惟深圳艾尼爾角膜工程有限公司及天津衛凱生物工程公司於截至二零一六年十二月三十一日止年度起計三個年度內作為高新技術企業而享有稅項優惠，只須按15%之優惠所得稅率繳稅。

Three months ended 31 July 截至七月三十一日止三個月

		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Profits Tax — for the period	利得稅 — 期內		
Hong Kong	香港	—	—
The PRC	中國	—	—
Deferred taxation	遞延稅項	(1,832)	(1,651)
Total income tax credit	總所得稅抵免	(1,832)	(1,651)

8. DIVIDENDS

The Board of Directors does not recommend the payment of dividends for the three months ended 31 July 2017 (2016: Nil).

8. 股息

董事會並不建議派付截至二零一七年七月三十一日止三個月之股息（二零一六年：無）。



9. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to owners of the Company is based on the following data:

9. 每股虧損

本公司擁有人應佔每股基本及攤薄虧損乃根據以下數據計算：

		Three months ended 31 July 截至七月三十一日止三個月	
		2017 二零一七年 HK\$'000 千港元 Unaudited 未經審核	2016 二零一六年 HK\$'000 千港元 Unaudited 未經審核
Loss for the period attributable to owners of the Company for the purpose of basic loss per share	用以計算每股基本虧損之本公司擁有人應佔期內虧損	(61,255)	76,355
Number of shares 股份數目		2017 二零一七年 '000 千股	2016 二零一六年 '000 千股
Weighted average number of ordinary shares for the purpose of basic loss per share	用以計算每股基本虧損之普通股加權平均數	17,585,790	17,592,180

For the three months ended 31 July 2017 and 2016, diluted losses per share attributable to owners of the Company were not presented because the impact of the exercise of share options was anti-dilutive.

截至二零一七年及二零一六年七月三十一日止三個月，由於行使購股權具反攤薄影響，故並無呈列有關本公司擁有人應佔每股攤薄虧損。

10. OPERATING LEASE COMMITMENTS

As lessee

The Group leases a number of properties under operating leases. The leases run for an initial period of one to five years.

At the reporting date, the total future minimum lease payments under non-cancellable operating leases are as follows:

		31 July 2017 二零一七年 七月三十一日 HK\$'000 千港元 Unaudited 未經審核	30 April 2017 二零一七年 四月三十日 HK\$'000 千港元 Audited 經審核
Within one year	一年內	27,666	26,445
In the second to fifth year inclusive	第二至第五年 (包括首尾兩年)	40,263	44,962
		67,929	71,407

During the year ended 30 April 2017, the Group entered into framework agreements with independent third parties to establish an ophthalmic clinic and a specialist hospital located in Shenzhen, PRC. According to the terms of the two framework agreements, the Group may use each of the two sites for the first eight years following the date when the relevant site becomes available for use and the Group is required to share 49% of the audited net profit (after tax) of the specialist hospital with the independent third party during the term of that lease. Thereafter, the Group may elect to continue to rent the sites at a rate to be determined by reference to the then prevailing market rate for the seven years that follow.

10. 經營租賃承擔

作為承租方

本集團根據經營租賃租用若干物業。有關租賃初始期為一至五年。

於報告日，根據不可撤銷經營租賃而須支付之未來最低租金總額如下：

於截至二零一七年四月三十日止年度，本集團與獨立第三方訂立框架協議，以於中國深圳成立一間眼科診所及一間專科醫院。根據兩份框架協議之條款，本集團可於有關場所可供使用之日起首個八年內使用該兩個場所，但本集團須於租賃年期內與獨立第三方分享專科醫院49%經審核淨利潤（稅後）。此後，本集團可選擇繼續租賃該等場所，租金將參考七年後的通行市場利率釐定。



11. CAPITAL AND OTHER COMMITMENTS

At the reporting date, the Group had capital and other commitments as follows:

		31 July 2017 二零一七年 七月三十一日 HK\$'000 千港元 Unaudited 未經審核	30 April 2017 二零一七年 四月三十日 HK\$'000 千港元 Audited 經審核
Capital commitments:	資本承擔:		
Authorised but not contracted for: Purchase of property, plant and equipment	已授權但未訂約: 購置物業、廠房 及設備	—	—
Contracted but not provided for: Purchase of property, plant and equipment	已訂約但未撥備: 購置物業、廠房 及設備	10,799	15,038

The Company signed two sponsorship agreements with the University of Oxford for the research of stem cell therapy and tissue engineering. The Company agreed to pay GBP9.0 million (equivalent to HK\$102.6 million) to the University of Oxford by instalments over the period covered by the agreements. Up to 31 July 2017, the Company has paid GBP4.75 million (equivalent to HK\$52.6 million) (up to 30 April 2017: has paid GBP4.75 million (equivalent to HK\$52.6 million)) to the University of Oxford.

On 31 March 2017, the Group entered into a commitment letter with independent third parties to subscribe for the interest in Haitong International Zhong Hua Finance Acquisition Fund I, L.P. ("the Fund"), an exempted limited partnership to be established in the Cayman Islands, and irrevocably undertake to make a capital contribution of US\$75 million (equivalent to HK\$585 million) to the Fund as a limited partner of the Fund, subject to and assumes the satisfaction of the conditions contained in the limited partnership agreement and subscription agreement of the Fund and acceptance by the general partner of the Fund. Up to 31 July 2017, the Company has paid US\$10 million (equivalent to HK\$78.15 million) (30 April 2017: Nil) to the Fund. On 15 July 2017, the Group entered into the limited partnership agreement and subscription agreement of the Fund.

11. 資本及其他承擔


於報告日，本集團之資本及其他承擔如下：

		31 July 2017 二零一七年 七月三十一日 HK\$'000 千港元 Unaudited 未經審核	30 April 2017 二零一七年 四月三十日 HK\$'000 千港元 Audited 經審核
Capital commitments:	資本承擔:		
Authorised but not contracted for: Purchase of property, plant and equipment	已授權但未訂約: 購置物業、廠房 及設備	—	—
Contracted but not provided for: Purchase of property, plant and equipment	已訂約但未撥備: 購置物業、廠房 及設備	10,799	15,038

本公司與牛津大學就幹細胞治療及組織工程的研究訂立兩份贊助協議。本公司同意於協議涵蓋期間向牛津大學分期支付9,000,000英鎊（相當於102,600,000港元）。截至二零一七年七月三十一日，本公司已向牛津大學支付4,750,000英鎊（相當於52,600,000港元）（截至二零一七年四月三十日：已支付4,750,000英鎊（相當於52,600,000港元））。

於二零一七年三月三十一日，本集團與獨立第三方訂立認購Haitong International Zhong Hua Finance Acquisition Fund I, L.P.（「基金」）（為將於開曼群島成立之獲豁免有限責任合夥事業）權益的承擔函，並不可撤銷地承諾作為基金之有限合夥人向基金注資75,000,000美元（相當於585,000,000港元），惟須待基金之有限責任合夥協議及認購協議中所載之條件獲達成以及獲基金之普通合夥人接納後方可作實。截至二零一七年七月三十一日，本公司已向基金支付10,000,000美元（相當於78,150,000港元）（二零一七年四月三十日：無）。於二零一七年七月十五日，本集團訂立基金之有限責任合夥協議及認購協議。

BUSINESS REVIEW AND PROSPECTS



The Group's operation strategy continues to enhance sales and marketing development measures so as to further improve the business performance. Effective sales distribution channel and service network has been established gradually and improvements in sales and marketing performance of all product lines has been achieved. With overall streamlining the Group's existing product lines, the Group initiate the product upgrade strategy to achieve effective combination between product and market, product and service, product and brand, single product and whole industrial chain through the innovations of products, technology and operations.

FUTURE PROSPECT

The Group continues to strive for opportunity to widen its business scope in the medicine industries and reallocate its resources when appropriate, to strengthen and maintain as one of the leading pioneer in the medical and related industries. The Chinese government has committed to provide support towards hi-tech industries, including regenerative medicine, a sub-division of the bio-medical industries. We will continuously strive for more assistance from the Chinese government to provide additional resources for broadening our R&D coverage in regenerative medicine and related medical device spectrum.

As the Group continues to identify and invest in suitable business opportunities, expand and improve its R&D capability, facilitate the development of business plan and implement its sales and marketing strategy, the Board may consider fund raising activities if viable raising options, which are in the best interest of the Group and the shareholders of the Company, are available.

業務回顧及前景

本集團之營運策略為繼續加強市場銷售力度，以進一步提高經營業績。本集團已逐步形成有效的銷售分銷渠道及服務網絡體系，各產品線的市場銷售業績都有明顯的提高。經過對本集團現有產品線的全面梳理，本集團啟動了產品升級策略，通過產品創新、技術創新、經營創新的手段，實現產品與市場、產品與服務、產品與品牌、單一產品與全產業鏈的有效銜接。

未來前景

本集團將繼續爭取擴大其於醫學行業之業務範圍的機會，並適時重新分配其資源以加強和維持其在醫學及相關行業的領先地位。中國政府致力對高新技術產業提供支持，包括作為生物醫藥產業分支的再生醫學。我們將繼續爭取獲得中國政府更多的支持，為擴大我們於再生醫學及相關醫療器械領域之研發範圍提供額外資源。

本集團將繼續致力物色和投資於合適商機、擴大和提高其研發能力、促進發展現有業務計劃及實施銷售及營銷策略，在此過程中，董事會可能會在有符合本集團及本公司股東最佳利益的可行集資選擇時考慮進行集資活動。



FINANCIAL REVIEW

The Group's revenue for the three months period ended 31 July 2017 was approximately HK\$71.1 million, representing an increase of approximately HK\$68.4 million, or 2,533.3%, compared to revenue of approximately HK\$2.7 million for last period. The overall increase in revenue was primarily attributable to an increase in revenue in both tissue engineering, cosmetics and others and medical equipment segments. During the period under review, the Group incurred a loss of approximately HK\$68.0 million, as compared to a loss of approximately HK\$80.5 million for last period. The loss was mainly attributable to employee benefit expenses of HK\$40.9 million (2016: 33.4 million), advertising, marketing and promotion expenses of HK\$ 28.6 million (2016: HK\$2.5 million), amortisation and depreciation expenses of HK\$14.2 million (2016: HK\$13.0 million), exchange gain of HK\$0.7 million (2016: exchange loss of HK\$12.8 million) and research and development costs of HK\$8.1 million (2016: HK\$7.9 million), amongst others.

FOREIGN EXCHANGE EXPOSURE

The Group's business transactions, assets and liabilities are principally denominated in Renminbi and Hong Kong dollars. The Directors consider the risk of foreign exchange exposure of the Group is manageable. The management will continue to monitor the foreign exchange exposure of the Group and is prepared to take prudent measures such as hedging when appropriate actions are required.

財務回顧

本集團截至二零一七年七月三十一日止三個月期間之收益為約71,100,000港元，較上一期間約2,700,000港元增加約68,400,000港元或2,533.3%。收益整體增長主要由於組織工程、美容及其他以及醫療設備分部之收益均錄得增長。於回顧期間，本集團錄得虧損約68,000,000港元，而上一期間錄得虧損為約80,500,000港元。有關虧損乃主要歸因於（其中包括）僱員福利開支40,900,000港元（二零一六年：33,400,000港元）、廣告及市場推廣開支28,600,000港元（二零一六年：2,500,000港元）、攤銷及折舊開支14,200,000港元（二零一六年：13,000,000港元）、滙兌收益700,000港元（二零一六年：滙兌虧損12,800,000港元）以及研發成本8,100,000港元（二零一六年：7,900,000港元）。

外匯風險

本集團的業務交易、資產及負債主要以人民幣及港元計值。董事認為本集團之外匯風險受控。管理層將繼續監控本集團的滙兌風險，並準備於有需要時採取審慎措施，例如對沖。





MATERIAL ACQUISITIONS/ DISPOSAL OF SUBSIDIARIES AND ASSOCIATED COMPANIES

The Group had no material acquisitions/disposal of subsidiaries and associated companies during the period.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 31 July 2017, the following Directors and chief executives of the Company had or were deemed to have interest or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules related to securities transactions by the Directors to be notified to the Company and the Stock Exchange:

附屬公司及聯屬公司 之重大收購／出售 事項

於期內，本集團概無附屬公司及聯屬公司之重大收購／出售事項。

董事及最高行政人員 於股份及相關股份之 權益及淡倉

於二零一七年七月三十一日，下列董事及本公司最高行政人員於本公司及其相聯法團（定義見香港法例第571章證券及期貨條例（「證券及期貨條例」）第XV部）之股份、相關股份或債券中，擁有或被視作擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益或淡倉（包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉）；或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉；或(iii)根據創業板上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所之權益或淡倉：



LONG POSITIONS

Interests in the shares and underlying shares of the Company

好倉

於本公司股份及相關股份之權益

Name of Directors/ chief executives 董事／最高 行政人員姓名	Capacity 身份	Aggregate long position in the shares and underlying shares 於股份及相關股份 之好倉總計	Approximate percentage of the issued share capital 佔已發行股本 概約百分比
Wong Sai Hung (Note 1) 黃世雄(附註1)	Interests held jointly with another person 與其他人士共同持有的權益	30,000,000	0.17%
	Beneficial owner 實益擁有人	31,560,000	0.18%
Shao Zhengkang (Note 2) 邵政康(附註2)	Beneficial owner 實益擁有人	35,530,000	0.20%
Chen Chunguo (Note 3) 陳春國(附註3)	Beneficial owner 實益擁有人	500,000,000	2.84%
Cui Zhanfeng (Note 4) 崔占峰(附註4)	Beneficial owner 實益擁有人	78,630,000	0.45%
Wang Hui (Note 5) 王輝(附註5)	Beneficial owner 實益擁有人	3,850,000	0.02%
Lui Tin Nang (Note 6) 呂天能(附註6)	Beneficial owner 實益擁有人	4,500,000	0.03%
Pang Chung Fai Benny (Note 6) 彭中輝(附註6)	Beneficial owner 實益擁有人	4,410,000	0.03%
Chan Bing Woon (Note 6) 陳炳煥(附註6)	Beneficial owner 實益擁有人	4,230,000	0.02%

Notes:

1. Mr. Wong Sai Hung (“Mr. Wong”) is an executive Director and the vice-chairman of the Board. Mr. Wong’s interests are held jointly with his spouse. By virtue of the SFO, Mr. Wong and his spouse are deemed to be interested in 30,000,000 shares of the Company.

On 16 September 2015, Mr. Wong was granted 7,560,000 share options (the “Share Options”) by the Company under the share option scheme of the Company adopted on 14 September 2011 (the “Share Option Scheme”) entitling him to subscribe for 7,560,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, Mr. Wong was granted 24,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 24,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Wong on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Wong shall hold the 31,560,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Wong and his spouse, together with their deemed interest in the shares held jointly, shall be deemed to be interested in an aggregate of 61,560,000 shares of the Company as at 31 July 2017.

附註：

1. 黃世雄先生（「黃先生」）為執行董事兼董事會副主席。黃先生的權益乃與其配偶共同持有。根據證券及期貨條例，黃先生及其配偶被視為於30,000,000股本公司股份中擁有權益。

於二零一五年九月十六日，黃先生獲本公司根據於二零一一年九月十四日採納之本公司購股權計劃（「購股權計劃」）授予7,560,000份購股權（「購股權」），賦予其權利可按每股0.45港元之行使價認購7,560,000股本公司股份，惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日，黃先生獲本公司根據購股權計劃授予24,000,000份購股權，賦予其權利可按每股0.291港元之行使價認購24,000,000股本公司股份，惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月九日授予黃先生之購股權獲悉數行使，黃先生將作為實益擁有人持有31,560,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，黃先生及其配偶，連同彼等被視為於共同持有之股份中擁有之權益應被視為於合共61,560,000股本公司股份中擁有權益。



2. Dr. Shao Zhengkang (“Dr. Shao”) is an executive Director. Dr. Shao personally holds 500,000 shares of the Company.

On 16 September 2015, he was granted 12,030,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 12,030,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, he was granted 23,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 23,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Dr. Shao on 16 September 2015 and 9 September 2016 have been exercised in full, Dr. Shao shall hold an aggregate of 35,030,000 shares of the Company as beneficial owner.

By virtue of the SFO, Dr. Shao shall be deemed to be interested in an aggregate of 35,530,000 shares of the Company as at 31 July 2017.

3. Mr. Chen Chunguo (“Mr. Chen”) is an executive Director and the chief executive officer of the Company.

On 25 January 2017, he was conditionally granted 500,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for up to an aggregate of 500,000,000 shares of the Company at the exercise price of HK\$0.3025 per share, subject to the approval of the shareholders of the Company excluding Mr. Chen and his associates (the “Independent Shareholders”) in a general meeting of the Company and the terms and conditions of the Share Option Scheme. On 17 July 2017, the Independent Shareholders has approved the resolution at the extraordinary general meeting (the “EGM”).

2. 邵政康博士（「邵博士」）為執行董事。邵博士個人持有500,000股本公司股份。

於二零一五年九月十六日，彼獲本公司根據購股權計劃授予12,030,000份購股權，賦予其權利可按每股0.45港元之行使價認購12,030,000股本公司股份，惟須遵守購股權計劃之條款及條件。


於二零一六年九月九日，彼獲本公司根據購股權計劃授予23,000,000份購股權，賦予其權利可按每股0.291港元之行使價認購23,000,000股本公司股份，惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月九日授予邵博士的購股權獲悉數行使，邵博士將作為實益擁有人持有合共35,030,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，邵博士應被視為於合共35,530,000股本公司股份中擁有權益。

3. 陳春國先生（「陳先生」）為本公司執行董事兼行政總裁。

於二零一七年一月二十五日，彼獲本公司根據購股權計劃有條件授予500,000,000份購股權，賦予其權利可按每股0.3025港元之行使價認購合共最多500,000,000股本公司股份，惟須獲本公司股東（不包括陳先生及其聯繫人（「獨立股東」））於本公司股東大會上批准及遵守購股權計劃之條款及條件。於二零一七年七月十七日，獨立股東已於股東特別大會（「股東特別大會」）上批准該決議案。



Assuming the Share Options granted to Mr. Chen on 25 January 2017 have been exercised in full, Mr. Chen shall hold an aggregate of 500,000,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Chen shall be deemed to be interested in 500,000,000 shares of the Company as at 31 July 2017.

4. Professor Cui Zhanfeng ("Prof. Cui") is a non-executive Director and the chairman of the Board. Prof. Cui personally holds 65,000,000 shares of the Company.

On 16 September 2015, he was granted 9,630,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 9,630,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, he was granted 4,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 4,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Prof. Cui on 16 September 2015 and 9 September 2016 have been exercised in full, Prof. Cui shall hold an aggregate of 13,630,000 shares of the Company as beneficial owner.

By virtue of the SFO, Prof. Cui shall be deemed to be interested in an aggregate of 78,630,000 shares of the Company as at 31 July 2017.

假設於二零一七年一月二十五日授予陳先生的購股權獲悉數行使，陳先生將作為實益擁有人持有合共500,000,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，陳先生應被視為於500,000,000股本公司股份中擁有權益。

4. 崔占峰教授（「崔教授」）為非執行董事兼董事會主席。崔教授個人持有65,000,000股本公司股份。

於二零一五年九月十六日，彼獲本公司根據購股權計劃授予9,630,000份購股權，賦予其權利可按每股0.45港元之行使價認購9,630,000股本公司股份，惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日，彼獲本公司根據購股權計劃授予4,000,000份購股權，賦予其權利可按每股0.291港元之行使價認購4,000,000股本公司股份，惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月九日授予崔教授的購股權獲悉數行使，崔教授將作為實益擁有人持有合共13,630,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，崔教授應被視為於合共78,630,000股本公司股份中擁有權益。



5. On 16 September 2015, Mr. Wang Hui (“Mr. Wang”) is a non-executive Directors (who was re-designated from independent non-executive Director with effect from 1 June 2017), was granted 1,750,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 1,750,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, Mr. Wang, was granted 2,100,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 2,100,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Wang on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Wang shall hold 3,850,000 shares of the Company as beneficial owners.

By virtue of the SFO, Mr. Wang shall be deemed to be interested in 3,850,000 shares of the Company as at 31 July 2017.

6. On 16 September 2015, Mr. Lui Tin Nang (“Mr. Lui”), Mr. Pang Chung Fai Benny (“Mr. Pang”) and Mr. Chan Bing Woon (“Mr. Chan”) are the independent non-executive Directors, were granted 2,100,000, 2,010,000 and 1,930,000 Share Options respectively by the Company under the Share Option Scheme entitling each of them to subscribe for 2,100,000, 2,010,000 and 1,930,000 shares of the Company respectively at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

5. 於二零一五年九月十六日，非執行董事王輝先生（「王先生」），其於二零一七年六月一日起調任為獨立非執行董事）獲本公司根據購股權計劃授予1,750,000份購股權，賦予其權利可按每股0.45港元之行使價認購1,750,000股本公司股份，惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日，王先生獲本公司根據購股權計劃授予2,100,000份購股權，賦予其權利可按每股0.291港元之行使價認購2,100,000股本公司股份，惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月九日授予王先生的購股權獲悉數行使，王先生將作為實益擁有人持有3,850,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，王先生被視為於3,850,000股本公司股份中擁有權益。

6. 於二零一五年九月十六日，獨立非執行董事呂天能先生（「呂先生」）、彭中輝先生（「彭先生」）及陳炳煥先生（「陳先生」）分別獲本公司根據購股權計劃授予2,100,000份、2,010,000份及1,930,000份購股權，賦予彼等各自權利分別可按每股0.45港元之行使價認購2,100,000股、2,010,000股及1,930,000股本公司股份，惟須遵守購股權計劃之條款及條件。



On 9 September 2016, Mr. Lui, Mr. Pang and Mr. Chan, were granted 2,400,000, 2,400,000 and 2,300,000 Share Options respectively by the Company under the Share Option Scheme entitling each of them to subscribe for 2,400,000, 2,400,000 and 2,300,000 shares of the Company respectively at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Lui, Mr. Pang and Mr. Chan on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Lui, Mr. Pang and Mr. Chan shall hold 4,500,000, 4,410,000 and 4,230,000 shares of the Company respectively as beneficial owners.

By virtue of the SFO, Mr. Lui, Mr. Pang and Mr. Chan shall be deemed to be interested in 4,500,000, 4,410,000 and 4,230,000 shares of the Company respectively as at 31 July 2017.

Save as disclosed above, as at 31 July 2017, none of the Directors nor the chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by Directors to be notified to the Company and the Stock Exchange.

於二零一六年九月九日，呂先生、彭先生及陳先生分別獲本公司根據購股權計劃授予2,400,000份、2,400,000份及2,300,000份購股權，賦予彼等各自權利可分別按每股0.291港元之行使價認購2,400,000股、2,400,000股及2,300,000股本公司股份，惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月九日授予呂先生、彭先生及陳先生的購股權獲悉數行使，呂先生、彭先生及陳先生分別將作為實益擁有人持有4,500,000股、4,410,000股及4,230,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，呂先生、彭先生及陳先生將被視為分別於4,500,000股、4,410,000股及4,230,000股本公司股份中擁有權益。

除上文所披露者外，於二零一七年七月三十一日，概無董事或本公司最高行政人員於本公司及其相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份或債券中擁有或視作擁有任何(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益或淡倉（包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉）；或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉；或(iii)根據創業板上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所之權益或淡倉。



SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES

So far as known to the Directors, as at 31 July 2017, the following parties (not being the Directors or chief executives of the Company) had, or were deemed to have, interests or short positions in the shares, underlying shares or debentures of the Company (i) which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or (ii) which were required, pursuant to Section 336 of the SFO, to be entered in the register referred to therein:

主要股東及其他人士 於股份及相關股份之 權益

據董事所知，於二零一七年七月三十一日，下列人士（非董事或本公司最高行政人員）於本公司股份、相關股份或債券中，擁有或被視作擁有 (i) 根據證券及期貨條例第 XV 部第 2 及 3 分部之條文須向本公司及聯交所披露之權益或淡倉；或 (ii) 根據證券及期貨條例第 336 條須記入該條所述登記冊內之權益或淡倉：

LONG POSITIONS

Interests in the shares and underlying shares of the Company

好倉

於本公司股份及相關股份之權益

Name of Shareholders	Capacity	Aggregate long position in the shares and underlying shares 於股份及相關股份之好倉總計	Approximate percentage of the issued share capital 佔已發行股本概約百分比
股東姓名／名稱	身份		
China Orient Asset Management Co., Ltd (Note 7) 中國東方資產管理公司(附註7)	Held by controlled corporation 由受控法團持有	4,585,765,319	26.07%
All Favour (Note 8) 全輝(附註8)	Beneficial owner 實益擁有人	3,708,100,319	21.09%
Hu Yonggang (Note 8) 胡永剛(附註8)	Held by controlled corporation 由受控法團持有	3,708,100,319	21.09%
Dai Yumin (Note 8) 戴昱敏(附註8)	Held by controlled corporation 由受控法團持有	3,708,100,319	21.09%
	Held by his spouse 由配偶持有	7,715,000	0.04%
	Beneficial owner 實益擁有人	537,325,000	3.06%
China Dragon Asia Champion Fund Series SPC (Note 9) (附註9)	Investment manager 投資經理	1,270,929,300	7.23%




Notes:

7. Based on Form 2 filed on 25 July 2017 by China Orient Asset Management Co., Ltd (“COAMC”), Optimus Prime Management Ltd. (“Optimus”) has a security interest in 4,201,765,319 shares of the Company and China Orient Asset Management (International) Holding Limited (“COAMI”) has an interest in 384,000,000 shares of the Company. Optimus is wholly owned by COAMI. COAMI is owned as to (i) 50% by Wise Leader Assets Ltd. (“Wise Leader”) which is wholly owned by Dong Yin Development (Holdings) Limited (“Dong Yin”); and (ii) 50% by Dong Yin which is wholly owned by COAMC. By virtue of the SFO, Dong Yin, Wise Leader and COAMC are deemed to be interested in 384,000,000 shares of the Company held by COAMI, and COAMI, Dong Yin, Wise Leader and COAMC are deemed to be interested in 4,201,765,319 shares of the Company held by Optimus as security interest. As a result, Dong Yin, Wise Leader and COAMC are deemed to be interest in an aggregate of 4,585,765,319 shares of the Company as at 31 July 2017.
8. All Favour Holdings Limited (“All Favour”) is beneficially owned as to (i) 40% by Nat-Ace Wood Industry Ltd. (“Nat-Ace Wood Industry”) and 20% by Honour Top Holdings Limited which are both ultimately wholly owned by Mr. Dai Yumin (“Mr. Dai”), and (ii) 40% by Mr. Hu Yonggang (“Mr. Hu”). Moreover, All Favour has been the beneficial owner of 3,708,100,319 shares of the Company. By virtue of the SFO, Mr. Dai, Mr. Hu and Nat-Ace Wood Industry are deemed to be interested in 3,708,100,319 shares of the Company in which All Favour is interested as of 31 July 2017.

附註：

7. 根據中國東方資產管理公司（「東方資產」）於二零一七年七月二十五日提交的表格 2，Optimus Prime Management Ltd.（「Optimus」）於 4,201,765,319 股本公司股份中持有保證權益且中國東方資產管理（國際）控股有限公司（「東方國際」）於 384,000,000 股本公司股份中擁有權益。Optimus 由東方國際全資擁有。東方國際分別由 (i) Wise Leader Assets Ltd.（「Wise Leader」，由東銀發展（控股）有限公司（「東銀」）全資擁有）擁有 50%；及 (ii) 東銀（由東方資產全資擁有）擁有 50%。根據證券及期貨條例，東銀、Wise Leader 及東方資產被視為於東方國際持有的 384,000,000 股本公司股份中擁有權益，而東方國際、東銀、Wise Leader 及東方資產被視為於 Optimus 持有保證權益的 4,201,765,319 股本公司股份中擁有權益。因此，於二零一七年七月三十一日，東銀、Wise Leader 及東方資產被視為於合共 4,585,765,319 股本公司股份中擁有權益。
8. 全輝控股有限公司（「全輝」）由 (i) 邦強木業有限公司（「邦強木業」）實益擁有 40% 及 Honour Top Holdings Limited 實益擁有 20%，而彼等均由戴昱敏先生（「戴先生」）最終全資擁有；及 (ii) 胡永剛先生（「胡先生」）實益擁有 40%。此外，全輝為 3,708,100,319 股本公司股份之實益擁有人。根據證券及期貨條例，截至二零一七年七月三十一日，戴先生、胡先生及邦強木業被視為於全輝擁有權益的 3,708,100,319 股本公司股份中擁有權益。



Ms. Deng Shufen (“Ms. Deng”), the spouse of Mr. Dai has beneficial interests in 7,715,000 shares of the Company as at 31 July 2017. By virtue of the SFO, Mr. Dai was deemed to be interested in 7,715,000 shares of the Company held by Ms. Deng as at 31 July 2017.

On 16 September 2015, Mr. Dai was granted 17,500,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 17,500,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme. Moreover, Mr. Dai personally holds 519,825,000 shares of the Company. Assuming the Share Options granted to Mr. Dai has been exercised in full, Mr. Dai shall hold an aggregate of 537,325,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Dai, together with his deemed interests in Ms. Deng and All Favour, was deemed to be interested in an aggregate of 4,253,140,319 shares of the Company as at 31 July 2017.

The Company was informed by All Favour that it has pledged its interests in 3,708,100,319 shares of the Company in favour of Optimus Prime Management Ltd..

9. Based on Form 2 filed on 31 May 2017 by China Dragon Asia Champion Fund Serise SPC (“China Dragon”), China Dragon holds 1,270,929,300 shares of the Company as an Investment manager.

鄧淑芬女士（「鄧女士」），為戴先生之配偶，於二零一七年七月三十一日於7,715,000股本公司股份中實益擁有權益。根據證券及期貨條例，於二零一七年七月三十一日，戴先生被視為於鄧女士持有的7,715,000股本公司股份中擁有權益。

於二零一五年九月十六日，戴先生獲本公司根據購股權計劃授予17,500,000份購股權，賦予其權利可按每股0.45港元之行使價認購17,500,000股本公司股份，惟須遵守購股權計劃之條款及條件。此外，戴先生個人持有519,825,000股本公司股份。假設授予戴先生之購股權獲悉數行使，戴先生將作為實益擁有人持有合共537,325,000股本公司股份。

根據證券及期貨條例，於二零一七年七月三十一日，連同彼被視為於鄧女士及全輝擁有之權益，戴先生被視為於合共4,253,140,319股本公司股份中擁有權益。

本公司獲全輝告知，其已將其於3,708,100,319股本公司股份中的權益抵押予Optimus Prime Management Ltd.。

9. 根據China Dragon Asia Champion Fund Serise SPC（「China Dragon」）提交的日期為二零一七年五月三十一日的表格2，China Dragon作為投資經理持有1,270,929,300股本公司股份。



Save as disclosed above, as at 31 July 2017, the Directors are not aware that there is any other party (other than the Directors and the chief executives of the Company) who had, or was deemed to have, interests or short positions in the shares, underlying shares and debentures of the Company (i) which would fall to be disclosed to the Company and Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or (ii) which were required, pursuant to section 336 of the SFO, to be entered in the register referred to therein.

DIRECTOR'S RIGHT TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed under the heading "DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES" above, at no time during the reporting period were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company or of any other body corporate granted to any directors or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company or any of its subsidiaries a party to any arrangements to enable the Directors, their respective spouse or children under 18 years of age to acquire such rights in the Company or any other body corporate as at 31 July 2017.

COMPETING INTERESTS

None of the Directors or the substantial shareholders of the Company, or any of their respective close associates (as defined under the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group during the three months ended 31 July 2017.

除上文所披露者外，於二零一七年七月三十一日，董事概不知悉任何其他人士（董事及本公司最高行政人員除外）於本公司股份、相關股份及債權證中，擁有或被視作擁有(i)根據證券及期貨條例第XV部第2及3分部之條文須向本公司及聯交所披露之權益或淡倉；或(ii)根據證券及期貨條例第336條須記入該條所述登記冊內之權益或淡倉。

董事收購股份或債權證之權利

除上文「董事及最高行政人員於股份及相關股份之權益及淡倉」一節所披露者外，於報告期內任何時間，概無任何董事或彼等各自之配偶或未滿18歲之子女獲授或行使任何可透過購買本公司或任何其他法人團體之股份或債權證而獲益之權利；或於二零一七年七月三十一日，本公司、其控股公司或其任何附屬公司並無訂立任何安排，致使董事、彼等各自之配偶或未滿18歲之子女獲得本公司或任何其他法人團體之該等權利。

競爭權益

截至二零一七年七月三十一日止三個月，概無任何董事或本公司主要股東或任何彼等各自之緊密聯繫人（定義見創業板上市規則）於與本集團業務構成競爭或可能構成競爭之業務中擁有任何權益。

SHARE OPTIONS

The Share Option Scheme adopted by the Company on 14 September 2011 is for the primary purpose of providing incentives to directors and eligible employees of the Group.

The movements of Share Options granted by the Company on 16 September 2015, 9 September 2016 and 25 January 2017* under the Share Option Scheme up to (and inclusive of) 31 July 2017 was shown below:

購股權

於二零一一年九月十四日，本公司採納購股權計劃，主要目的為向本集團董事及合資格僱員提供獎勵。

截至二零一七年七月三十一日（包括該日），本公司於二零一五年九月十六日、二零一六年九月九日及二零一七年一月二十五日*根據購股權計劃授出之購股權變動如下：

Movement of Share Options during the year ended 31 July 2017
截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding	Granted	Exercised	Reclassified	Lapsed	Outstanding
					as at 30 April 2017					as at 31 July 2017
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	於二零一七年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	於二零一七年七月三十一日尚未行使
Directors 董事	16/9/2015 二零一五年 九月十六日	0.45	16 September 2016 to 15 September 2017 (both days inclusive) (the "1st Period") 二零一六年九月十六日至二零一七年九月十五日 (包括首尾兩日) (第一個期間)	Up to 20% ("1st Options") 最多 20% (第一份購股權)	37,010,000	NIL 無	NIL 無	NIL 無	NIL 無	37,010,000
			16 September 2017 to 15 September 2018 (both days inclusive) (the "2nd Period") 二零一七年九月十六日至二零一八年九月十五日 (包括首尾兩日) (第二個期間)	Up to 20% ("2nd Options") (together with any 1st Options which have not been exercised during the 1st Period) 最多 20% (第二份購股權) (連同於第一個期間尚未行使之任何第一份購股權)						
			16 September 2018 to 15 September 2019 (both days inclusive) (the "3rd Period") 二零一八年九月十六日至二零一九年九月十五日 (包括首尾兩日) (第二個期間)	Up to 20% ("3rd Options") (together with any 1st and 2nd Options which have not been exercised during the 1st Period and 2nd Period) 最多 20% (第三份購股權) (連同於第一個期間及第二個期間尚未行使之任何第一份及第二份購股權)						

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	於二零一七年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	於二零一七年七月三十一日尚未行使

16 September 2019 to 15 September 2020 (both days inclusive) (the "4th Period")
二零一九年九月十六日至二零二零年九月十五日 (包括首尾兩日) (「第四個期間」)

Up to 20% ("4th Options") (together with any 1st, 2nd and 3rd Options which have not been exercised during the 1st Period, 2nd Period and 3rd Period) (最多 20% (「第四份購股權」) (連同於第一個期間、第二個期間及第三個期間尚未行使之任何第一份、第二份及第三份購股權))

16 September 2020 to 15 September 2025 (both days inclusive) (the "5th Period")
二零二零年九月十六日至二零二五年九月十五日 (包括首尾兩日) (「第五個期間」)

Up to 20% ("5th Options") (together with any 1st, 2nd, 3rd and 4th Options which have not been exercised during the 1st Period, 2nd Period, 3rd Period and 4th Period) (最多 20% (「第五份購股權」) (連同於第一個期間、第二個期間、第三個期間及第四個期間尚未行使之任何第一份、第二份、第三份及第四份購股權))

9/9/2016
二零一六年
九月九日

0.291

9 September 2017 to 8 September 2018 (both days inclusive) (the "First Period")
二零一七年九月九日至二零一八年九月八日 (包括首尾兩日) (「第一個期間」)

Up to 20% ("First Options") (最多 20% (「第一份購股權」))

60,200,000

NIL
無

NIL
無

NIL
無

NIL
無

60,200,000

9 September 2018 to 8 September 2019 (both days inclusive) (the "Second Period")
二零一八年九月九日至二零一九年九月八日 (包括首尾兩日) (「第二個期間」)

Up to 20% ("Second Options") (together with any First Options which have not been exercised during the First Period) (最多 20% (「第二份購股權」) (連同於第一個期間尚未行使之任何第一份購股權))

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	於二零一七年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	於二零一七年七月三十一日尚未行使
			9 September 2019 to 8 September 2020 (both days inclusive) (the "Third Period") 二零一九年九月九日至二零二零年九月八日 (包括首尾兩日) (第二個期間)	Up to 20% ("Third Options") (together with any First and Second Options which have not been exercised during the First Period and Second Period) 最多20% (第三份購股權) (連同於第一個期間及第二個期間尚未行使之任何第一份及第二份購股權)						
			9 September 2020 to 8 September 2021 (both days inclusive) (the "Fourth Period") 二零二零年九月九日至二零二一年九月八日 (包括首尾兩日) (第四個期間)	Up to 20% ("Fourth Options") (together with any First, Second and Third Options which have not been exercised during the First Period, Second Period and Third Period) 最多20% (第四份購股權) (連同於第一個期間、第二個期間及第三個期間尚未行使之任何第一份、第二份及第三份購股權)						
			9 September 2021 to 8 September 2025 (both days inclusive) (the "Fifth Period") 二零二一年九月九日至二零二五年九月八日 (包括首尾兩日) (第五個期間)	Up to 20% ("Fifth Options") (together with any First, Second, Third and Fourth Options which have not been exercised during the First Period, Second Period, Third Period and Fourth Period) 最多20% (第五份購股權) (連同於第一個期間、第二個期間、第三個期間及第四個期間尚未行使之任何第一份、第二份、第三份及第四份購股權)						

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017	Granted	Exercised	Reclassified	Lapsed	Outstanding as at 31 July 2017
					於二零一七年四月三十日尚未行使					於二零一七年七月三十一日尚未行使
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	500,000,000	無	無	無	無	500,000,000
	25/1/2017* 二零一七年一月二十五日*	0.3025	1 August 2019 to 31 July 2020 (both days inclusive) (the "A Period") 二零一九年八月一日至二零二零年七月三十一日 (包括首尾兩日) (A期間)	Up to 30% ("A Options") 最多30% (A類購股權)	500,000,000	NIL 無	NIL 無	NIL 無	NIL 無	500,000,000
			1 August 2020 to 31 July 2021 (both days inclusive) (the "B Period") 二零二零年八月一日至二零二一年七月三十一日 (包括首尾兩日) (B期間)	Up to 30% ("B Options") (together with any A Options which have not been exercised during the A Period) 最多30% (B類購股權) (連同於A期間尚未行使之任何A類購股權)						
			1 August 2021 to 24 January 2027 (both days inclusive) (the "C Period") 二零二一年八月一日至二零二七年一月二十四日 (包括首尾兩日) (C期間)	Up to the remaining balance of the options granted (together with any A and B Options which have not been exercised during the A Period and B Period) 最多為已授出購股權之結餘 (連同於A期間及B期間尚未行使之任何A類及B類購股權)						
Others 其他	16/9/2015 二零一五年九月十六日	0.45	For Grantees other than new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be): 就於招冊授出日期之承授人 (除加入本公司少於十二個月或仍未開始於本公司任職之新僱員外) 而言 (視情況而定): -		99,560,000	NIL 無	NIL 無	NIL 無	(1,830,000)	97,730,000
			1st Period 第一個期間	1st Options 第一份購股權						
			2nd Period 第二個期間	2nd Options (together with any 1st Options which have not been exercised during the 1st Period) 第二份購股權 (連同於第一個期間尚未行使之任何第一份購股權)						

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	2017年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	2017年七月三十一日尚未行使
			3rd Period 第三個期間	3rd Options (together with any 1st and 2nd Options which have not been exercised during the 1st Period and 2nd Period) 第三份購股權 (連同於第一個期間及第二個期間尚未行使之任何第一份及第二份購股權)						
			4th Period 第四個期間	4th Options (together with any 1st, 2nd and 3rd Options which have not been exercised during the 1st Period, 2nd Period and 3rd Period) 第四份購股權 (連同於第一個期間、第二個期間及第三個期間尚未行使之任何第一份、第二份及第三份購股權)						
			5th Period 第五個期間	5th Options (together with any 1st, 2nd, 3rd and 4th Options which have not been exercised during the 1st Period, 2nd Period, 3rd Period and 4th Period) 第五份購股權 (連同於第一個期間、第二個期間、第三個期間及第四個期間尚未行使之任何第一份、第二份、第三份及第四份購股權)						

Movement of Share Options during the year ended 31 July 2017
截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

For Grantees who are new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be):—

就於相關授出日期之承授人 (為加入本公司少於十二個月或仍未開始於本公司任職之新僱員) 而言 (視情況而定):—

16 March 2017 to 15 March 2018 (both days inclusive) (the "Period 1") 二零一七年三月十六日至二零一八年三月十五日 (包括首尾兩日) (「期間1」)	Up to 20% ("Options 1") 最多20% (「購股權1」)
16 March 2018 to 15 March 2019 (both days inclusive) (the "Period 2") 二零一八年三月十六日至二零一九年三月十五日 (包括首尾兩日) (「期間2」)	Up to 20% ("Options 2") (together with any Options 1 which have not been exercised during the Period 1) 最多20% (「購股權2」) (連同於期間1尚未行使之任何購股權1)
16 March 2019 to 15 March 2020 (both days inclusive) (the "Period 3") 二零一九年三月十六日至二零二零年三月十五日 (包括首尾兩日) (「期間3」)	Up to 20% ("Options 3") (together with any Options 1 and 2 which have not been exercised during the Periods 1 and 2) 最多20% (「購股權3」) (連同於期間1及2尚未行使之任何購股權1及2)
16 March 2020 to 15 March 2021 (both days inclusive) (the "Period 4") 二零二零年三月十六日至二零二一年三月十五日 (包括首尾兩日) (「期間4」)	Up to 20% ("Options 4") (together with any Options 1, 2 and 3 which have not been exercised during the Periods 1, 2 and 3) 最多20% (「購股權4」) (連同於期間1、2及3尚未行使之任何購股權1、2及3)

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	於二零一七年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	於二零一七年七月三十一日尚未行使
			16 March 2021 to 15 September 2025 (both days inclusive) 二零二一年三月十六日至二零二五年九月十五日 (包括首尾兩日)	Up to 20% (together with any Options 1, 2, 3 and 4 which have not been exercised during the Periods 1, 2, 3 and 4) 最多20% (連同於期間1、2、3及4尚未行使之任何購股權1、2、3及4)						
	9/9/2016 二零一六年九月九日	0.291	<i>For Grantees other than new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be) –</i> <i>就於相關授出日期之承授人 (除加入本公司少於十二個月或仍未開始於本公司任職之新僱員外) 而言 (視情況而定) :-</i>		139,030,000	NIL 無	NIL 無	NIL 無	(13,360,000)	125,670,000
			the First Period 第一個期間	the First Options 第一份購股權						
			the Second Period 第二個期間	the Second Options (together with any First Options which have not been exercised during the First Period) 第二份購股權 (連同於第一個期間尚未行使之任何第一份購股權)						
			the Third Period 第三個期間	the Third Options (together with any First and Second Options which have not been exercised during the First Period and Second Period) 第三份購股權 (連同於第一個期間及第二個期間尚未行使之任何第一份及第二份購股權)						

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	2017 於 二零一七年 四月三十日 尚未行使	已授出	已行使	已重新分類	已失效	2017 於 二零一七年 七月三十一日 尚未行使

the Fourth Period
第四個期間

the Fourth Options (together with any First, Second and Third Options which have not been exercised during the First Period, Second Period and Third Period)
第四份購股權 (連同於第一個期間、第二個期間及第三個期間尚未行使之任何第一份、第二份及第三份購股權)

the Fifth Period
第五個期間

the Fifth Options (together with any First, Second, Third and Fourth Options which have not been exercised during the First Period, Second Period, Third Period and Fourth Period)
第五份購股權 (連同於第一個期間、第二個期間、第三個期間及第四個期間尚未行使之任何第一份、第二份、第三份及第四份購股權)

For Grantees who are new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be) –

就於相關授出日期之承授人 (為加入本公司少於十二個月或仍未開始於本公司任職之新僱員) 而言 (視情況而定)：–

9 March 2018 to 8 March 2019 (both days inclusive) (the "1 Period")
二零一八年三月九日至二零一九年三月八日 (包括首尾兩日) (1 期間)

Up to 20% ("Options I")
最多 20% (1 購股權 I)

Movement of Share Options during the year ended 31 July 2017

截至二零一七年七月三十一日止年度之購股權變動

Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2017				Outstanding as at 31 July 2017	
					Granted	Exercised	Reclassified	Lapsed		
合資格人士	授出日期	行使價 (港元)	購股權之歸屬時間表及可行使期間	已授出購股權之可行使部份	2017 於二零一七年四月三十日尚未行使	已授出	已行使	已重新分類	已失效	2017 於二零一七年七月三十一日尚未行使
			9 March 2019 to 8 March 2020 (both days inclusive) (the "I Period") 二零一九年三月九日至二零二零年三月八日 (包括首尾兩日) (I 期間)	Up to 20% ("Options I") (together with any Options which have not been exercised during the I Period) 最多 20% (I 購股權 I) (連同於 I 期間 I 尚未行使之任何購股權 I)						
			9 March 2020 to 8 March 2021 (both days inclusive) (the "III Period") 二零二零年三月九日至二零二一年三月八日 (包括首尾兩日) (I 期間 III)	Up to 20% ("Options III") (together with any Options I and II which have not been exercised during the I and II Periods) 最多 20% (I 購股權 III) (連同於 I 及 II 期間 I 及 II 尚未行使之任何購股權 I 及 II)						
			9 March 2021 to 8 March 2022 (both days inclusive) (the "IV Period") 二零二一年三月九日至二零二二年三月八日 (包括首尾兩日) (I 期間 IV)	Up to 20% ("Options IV") (together with any Options I, II and III which have not been exercised during the I, II and III Periods) 最多 20% (I 購股權 IV) (連同於 I、II 及 III 期間 I、II 及 III 尚未行使之任何購股權 I、II 及 III)						
			9 March 2022 to 8 September 2025 (both days inclusive) 二零二二年三月九日至二零二五年九月八日 (包括首尾兩日)	Up to 20% (together with any Options I, II, III and IV which have not been exercised during the I, II, III and IV Periods) 最多 20% (連同於 I、II、III 及 IV 期間 I、II、III 及 IV 尚未行使之任何購股權 I、II、III 及 IV)						



* References are made to the announcements of the Company dated 25 January 2017, 20 March 2017 and the circular dated 26 June 2017 in relation to the conditional grant of Share Options to Mr. Chen Chunguo to subscribe for up to an aggregate of 500,000,000 ordinary shares. On 17 July 2017, the Independent Shareholders has approved the resolution at the EGM, please refer to the announcement dated 17 July 2017 for details.

* 茲提述本公司日期為二零一七年一月二十五日、二零一七年三月二十日之公告及日期為二零一七年六月二十六日之通函，內容有關向陳春國先生有條件授出可認購合共最多500,000,000股普通股之購股權。於二零一七年七月十七日，獨立股東已於股東特別大會上批准該決議案，詳情請參閱日期為二零一七年七月十七日之公告。

AUDIT COMMITTEE

The audit committee of the Company (the “Audit Committee”) has eight members, comprising all non-executive Directors (including independent non-executive Directors), namely Mr. Lui Tin Nang (the chairman of the Audit Committee), Professor Cui Zhanfeng, Dr. Ray Yip, Professor Xiong Chengyu, Mr. Wang Hui, Mr. Pang Chung Fai Benny, Mr. Chan Bing Woon and Mr. Wong Yiu Kit Ernest. The Company’s unaudited consolidated results for the three months ended 31 July 2017 have been reviewed by the Audit Committee.

審核委員會

本公司之審核委員會（「審核委員會」）有八位成員，包括所有非執行董事（包括獨立非執行董事），即呂天能先生（審核委員會主席）、崔占峰教授、葉雷博士、熊澄宇教授、王輝先生、彭中輝先生、陳炳煥先生及黃耀傑先生。審核委員會已審閱本公司截至二零一七年七月三十一日止三個月之未經審核綜合業績。

PURCHASE, SALE OR REDEMPTION OF SECURITIES

During the three months ended 31 July 2017 neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company’s listed securities.

購買、出售或贖回證券

截至二零一七年七月三十一日止三個月，本公司及其任何附屬公司概無購買、贖回或出售本公司任何上市證券。

By Order of the Board of
China Regenerative Medicine International Limited
Wong Sai Hung
Executive Director

承董事會命
中國再生醫學國際有限公司
執行董事
黃世雄

Hong Kong, 8 September 2017

香港，二零一七年九月八日



As at the date of this report, the executive Directors are Mr. Chen Chunguo, Mr. Wong Sai Hung and Dr. Ray Yip; the non-executive Directors are Professor Cui Zhanfeng and Professor Xiong Chengyu; and the independent non-executive Directors are Mr. Chan Bing Woon, SBS, JP, Mr. Wong Yiu Kit Ernest, Mr. Lui Tin Nang and Mr. Pang Chung Fai Benny.

This report will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the website of the Company at www.crimi.hk.

於本報告日期，執行董事為陳春國先生、黃世雄先生及葉雷博士；非執行董事為崔占峰教授及熊澄宇教授；及獨立非執行董事為陳炳煥先生（銀紫前星章、太平紳士）、黃耀傑先生、呂天能先生及彭中輝先生。

本報告將由刊發日期起計至少保留七日於創業板網站 www.hkgem.com 之「最新公司公告」一頁及於本公司之網站 www.crimi.hk 內登載。

**China Regenerative Medicine
International Limited**

中國再生醫學國際有限公司

www.crimi.hk

刊發業績公告

本季度業績公告可於創業板的網站 www.hkgem.com 及本公司的網站 www.crimi.hk 閱覽。

承董事會命
中國再生醫學國際有限公司
執行董事
黃世雄

香港，二零一七年九月八日

於本公告日期，執行董事為陳春國先生、黃世雄先生及葉雷博士；非執行董事為崔占峰教授及熊澄宇教授；及獨立非執行董事為陳炳煥先生（銀紫荊星章、太平紳士）、黃耀傑先生、呂天能先生及彭中輝先生。

本公告的資料乃遵照創業板上市規則而刊載，旨在提供有關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。董事在作出一切合理查詢後，確認就其所知及所信，本公告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何其他事項，足以令致本公告或其所載任何陳述產生誤導。

本公告將由刊發日期起計至少保留七日於創業板網站 www.hkgem.com 之「最新公司公告」一頁及於本公司之網站 www.crimi.hk 內登載。